FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386019227> ?p ?o ?g. }

• W4386019227 abstract "Abstract Background Medulloblastoma (MB) is the most common cerebellar malignancy during childhood. Among MB, MYC-amplified Group 3 tumors display the worst prognosis. MYC is an oncogenic transcription factor currently thought to be undruggable. Nevertheless, targeting MYC-dependent processes (i.e. transcription and RNA processing regulation) represents a promising approach. Methods We have tested the sensitivity of MYC-driven Group 3 MB cells to a pool of transcription and splicing inhibitors that display a wide spectrum of targets. Among them, we focus on THZ531, an inhibitor of the transcriptional cyclin-dependent kinases (CDK) 12 and 13. High-throughput RNA-sequencing analyses followed by bioinformatics and functional analyses were carried out to elucidate the molecular mechanism(s) underlying the susceptibility of Group 3 MB to CDK12/13 chemical inhibition. Data from International Cancer Genome Consortium (ICGC) and other public databases were mined to evaluate the functional relevance of the cellular pathway/s affected by the treatment with THZ531 in Group 3 MB patients. Results We found that pharmacological inhibition of CDK12/13 is highly selective for MYC-high Group 3 MB cells with respect to MYC-low MB cells. We identified a subset of genes enriched in functional terms related to the DNA damage response (DDR) that are up-regulated in Group 3 MB and repressed by CDK12/13 inhibition. Accordingly, MYC- and CDK12/13-dependent higher expression of DDR genes in Group 3 MB cells limits the toxic effects of endogenous DNA lesions in these cells. More importantly, chemical inhibition of CDK12/13 impaired the DDR and induced irreparable DNA damage exclusively in MYC-high Group 3 MB cells. The augmented sensitivity of MYC-high MB cells to CDK12/13 inhibition relies on the higher elongation rate of the RNA polymerase II in DDR genes. Lastly, combined treatments with THZ531 and DNA damage-inducing agents synergically suppressed viability of MYC-high Group 3 MB cells. Conclusions Our study demonstrates that CDK12/13 activity represents an exploitable vulnerability in MYC-high Group 3 MB and may pave the ground for new therapeutic approaches for this high-risk brain tumor." @default.
• W4386019227 created "2023-08-22" @default.
• W4386019227 creator A5004513190 @default.
• W4386019227 creator A5018205523 @default.
• W4386019227 creator A5020165825 @default.
• W4386019227 creator A5020418933 @default.
• W4386019227 creator A5022961395 @default.
• W4386019227 creator A5025974014 @default.
• W4386019227 creator A5026388627 @default.
• W4386019227 creator A5042421399 @default.
• W4386019227 creator A5053517115 @default.
• W4386019227 creator A5061164548 @default.
• W4386019227 creator A5071758084 @default.
• W4386019227 creator A5091236017 @default.
• W4386019227 date "2023-08-21" @default.
• W4386019227 modified "2023-10-18" @default.
• W4386019227 title "MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma" @default.
• W4386019227 cites W1263857580 @default.
• W4386019227 cites W127046385 @default.
• W4386019227 cites W1966901253 @default.
• W4386019227 cites W1976021822 @default.
• W4386019227 cites W2004326614 @default.
• W4386019227 cites W2114104545 @default.
• W4386019227 cites W2123814549 @default.
• W4386019227 cites W2140642045 @default.
• W4386019227 cites W2167212154 @default.
• W4386019227 cites W2169456326 @default.
• W4386019227 cites W2171613528 @default.
• W4386019227 cites W2179438025 @default.
• W4386019227 cites W2512442926 @default.
• W4386019227 cites W2556688586 @default.
• W4386019227 cites W2596064219 @default.
• W4386019227 cites W2626440326 @default.
• W4386019227 cites W2737542366 @default.
• W4386019227 cites W2769445989 @default.
• W4386019227 cites W2784382470 @default.
• W4386019227 cites W2796827074 @default.
• W4386019227 cites W2797725119 @default.
• W4386019227 cites W2806593114 @default.
• W4386019227 cites W2885067288 @default.
• W4386019227 cites W2896424253 @default.
• W4386019227 cites W2923931114 @default.
• W4386019227 cites W2944076627 @default.
• W4386019227 cites W2952112291 @default.
• W4386019227 cites W2952306492 @default.
• W4386019227 cites W2970073459 @default.
• W4386019227 cites W2978420094 @default.
• W4386019227 cites W2981873089 @default.
• W4386019227 cites W2991125500 @default.
• W4386019227 cites W2996632338 @default.
• W4386019227 cites W3007097494 @default.
• W4386019227 cites W3007726005 @default.
• W4386019227 cites W3021695369 @default.
• W4386019227 cites W3092475546 @default.
• W4386019227 cites W3126515736 @default.
• W4386019227 cites W3133777844 @default.
• W4386019227 cites W3145969289 @default.
• W4386019227 cites W3153375892 @default.
• W4386019227 cites W3158318541 @default.
• W4386019227 cites W3169813952 @default.
• W4386019227 cites W3174246647 @default.
• W4386019227 cites W3179561651 @default.
• W4386019227 cites W3211359479 @default.
• W4386019227 cites W3216529410 @default.
• W4386019227 cites W4200129720 @default.
• W4386019227 cites W4200543380 @default.
• W4386019227 cites W4210779433 @default.
• W4386019227 cites W4211218067 @default.
• W4386019227 cites W4220759822 @default.
• W4386019227 cites W4220788861 @default.
• W4386019227 cites W4286007925 @default.
• W4386019227 cites W4309912258 @default.
• W4386019227 cites W4362692520 @default.
• W4386019227 cites W4377093231 @default.
• W4386019227 doi "https://doi.org/10.1186/s13046-023-02790-2" @default.
• W4386019227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37599362" @default.
• W4386019227 hasPublicationYear "2023" @default.
• W4386019227 type Work @default.
• W4386019227 citedByCount "0" @default.
• W4386019227 crossrefType "journal-article" @default.
• W4386019227 hasAuthorship W4386019227A5004513190 @default.
• W4386019227 hasAuthorship W4386019227A5018205523 @default.
• W4386019227 hasAuthorship W4386019227A5020165825 @default.
• W4386019227 hasAuthorship W4386019227A5020418933 @default.
• W4386019227 hasAuthorship W4386019227A5022961395 @default.
• W4386019227 hasAuthorship W4386019227A5025974014 @default.
• W4386019227 hasAuthorship W4386019227A5026388627 @default.
• W4386019227 hasAuthorship W4386019227A5042421399 @default.
• W4386019227 hasAuthorship W4386019227A5053517115 @default.
• W4386019227 hasAuthorship W4386019227A5061164548 @default.
• W4386019227 hasAuthorship W4386019227A5071758084 @default.
• W4386019227 hasAuthorship W4386019227A5091236017 @default.
• W4386019227 hasBestOaLocation W43860192271 @default.
• W4386019227 hasConcept C104317684 @default.
• W4386019227 hasConcept C134935766 @default.
• W4386019227 hasConcept C138885662 @default.
• W4386019227 hasConcept C143425029 @default.
• W4386019227 hasConcept C153911025 @default.
• W4386019227 hasConcept C179926584 @default.
• W4386019227 hasConcept C2778502085 @default.

• next